HEALTH professionals and consumers are being advised that the Therapeutic Goods Administration (TGA) is investigating a safety concern regarding the Therakos Cellex Photopheresis System.
There have been 13 reports associated with the Therakos Cellex Photopheresis System mainly highlighting an increased risk of venous thromboembolism sometimes leading to pulmonary emboli, in two cases of which the patients died.
The system is an extracorporeal photopheresis (ECP) device that extracts, treats and returns a patient's blood, used especially in treatment of cutaneous T-cell lymphoma, transplant rejection situations and others.
Visit tga.gov.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Feb 18
